Perseus Proteomics Inc.
4882 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 目黒区駒場四丁目７番６号
- Website:
- https://www.ppmx.com/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Perseus Proteomics Inc. is an innovative biotechnology company based in Japan, dedicated to advancing global healthcare through cutting-edge antibody technologies. Focused on antibody drug discovery, the company aims to develop novel therapeutic solutions for various diseases. Perseus Proteomics offers a range of services, including drug discovery, antibody research support, and sales of antibodies and reagents, such as ELISA kits for PTX3 measurement. With a commitment to scientific excellence and sustainability, the company is actively involved in research and development, fostering collaborations to enhance its pipeline and impact in the biopharmaceutical industry. Perseus Proteomics strives to improve patient outcomes worldwide by leveraging its unique expertise in antibody technologies.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-27 09:28 |
Inside Information Statement
臨時報告書
|
Japanese | 25.9 KB | |
| 2025-06-27 08:34 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-06-27 08:33 |
Regulatory News Service
訂正有価証券報告書－第24期(2023/04/01－2024/03/31)
|
Japanese | 1.5 MB | |
| 2025-06-27 08:33 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-06-27 08:32 |
Regulatory News Service
訂正有価証券報告書－第23期(2022/04/01－2023/03/31)
|
Japanese | 1.5 MB | |
| 2025-06-27 08:32 |
Internal Control over Financial Reporting
内部統制報告書－第25期(2024/04/01－2025/03/31)
|
Japanese | 22.4 KB | |
| 2025-06-27 08:31 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2025-06-27 08:31 |
Annual Report
有価証券報告書－第25期(2024/04/01－2025/03/31)
|
Japanese | 2.6 MB | |
| 2025-05-21 08:31 |
Inside Information Statement
臨時報告書
|
Japanese | 20.2 KB | |
| 2024-11-14 07:34 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-11-14 07:34 |
Interim Report
半期報告書－第25期(2024/04/01－2025/03/31)
|
Japanese | 163.4 KB | |
| 2024-06-20 07:40 |
Inside Information Statement
臨時報告書
|
Japanese | 23.6 KB | |
| 2024-06-20 07:34 |
Internal Control over Financial Reporting
内部統制報告書－第24期(2023/04/01－2024/03/31)
|
Japanese | 21.2 KB | |
| 2024-06-20 07:34 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-06-20 07:33 |
Annual Report
有価証券報告書－第24期(2023/04/01－2024/03/31)
|
Japanese | 2.8 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |